Latest Genzyme Corporation Stories

CARLSBAD, Calif., May 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 UBS Global Healthcare Conference on Monday, May 20, 2013 at 9:00 a.m. ET in New York, NY. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the Isis Web...

- Conference Call Webcast Tuesday, May 7, 4:30 p.m. ET at www.isispharm.com CARLSBAD, Calif., May 7, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.5 million and pro forma net income of $1.2 million for the three months ended March 31, 2013 compared to a pro forma net operating loss of $16.2 million and a pro forma net loss of $21.7 million for the same period in 2012. The significant improvement in the Company's...

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics(TM)--a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins--announced today that Henri A. Termeer, Genzyme's retired chairman, president, and CEO, has joined Moderna's board of directors. Over nearly 30 years at Genzyme, Termeer built one of the world's most innovative and commercially successful biotechnology...

CARLSBAD, Calif., April 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 12(th) Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 11:20 a.m. ET in New York, NY. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the...

CARLSBAD, Calif., March 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application (MAA) for KYNAMRO(TM) (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia...

CARLSBAD, Calif., March 15, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 25(th) Annual ROTH Conference on Tuesday, March 19, 2013 at 8:00 a.m. PT in Laguna Niguel, CA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the Isis Web site...

- Event and webcast scheduled on Thursday, March 21 at 7:30 a.m. Pacific Time CARLSBAD, Calif., March 14, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Thursday, March 21, 2013 at 7:30 a.m. Pacific Time to discuss the ISIS-SMN(Rx) Phase 1 data presented at the 2013 American Academy of Neurology Annual Meeting. Interested parties may register to attend the event in San Diego, CA, or access the...

CARLSBAD, Calif., March 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 2:00 p.m. ET in Miami, FL. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the Isis Web...

- Conference Call Webcast Thursday, February 28, 12:00 p.m. ET at www.isispharm.com CARLSBAD, Calif., Feb. 28, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2012 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position significantly outperforming both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2012, Isis had an NOL of...

CARLSBAD, Calif., Feb. 27, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Cowen and Company 33(rd) Annual Health Care Conference on Wednesday, March 6, 2013 at 8:40 a.m. ET in Boston, MA. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available...